Tag: Palantir

Weekly Update

Weekly Market Overview – August 3-August 9, 2026

Palantir impresses with strong growth. The UMBRELLA strategy also focuses on healthcare, European defense, and structural trends.
Continue Umbrella
Weekly Update

Weekly Market Overview – August 17-August 23, 2026

Healthcare and AI provided support in a mixed week, while European defense stocks and SpaceX were more under pressure. There
Continue Umbrella
Weekly Update

Weekly Market Overview – August 24–August 30, 2026

Revolution Medicines reaches a major milestone with the FDA approval of RASONQUE, while PayPal saw significant price fluctuations following the
Continue Umbrella
Weekly Update

Weekly Market Overview – August 10-August 16, 2026

TKMS raises its outlook, SpaceX is added to the UMBRELLA strategy, thereby strengthening its focus on defense, AI, and the
Continue Umbrella
Weekly Update

Weekly Market Overview – May 25–31, 2026

The UMBRELLA Strategy is placing a stronger emphasis on AI, technology, healthcare, and defense. Tesla remains the largest single position.
Continue Umbrella
Palantir
Technology
USA

Valuation Analysis: Palantir Technologies

Palantir rapidly increases revenue, margins, and cash flow. The analysis highlights AI opportunities, defense business, and valuation risks.
Active icon
Continue Umbrella
Palantir
Technology
USA

Stock: Palantir Technologies

Palantir impressed in Q2 2026 with strong growth, record margins, and a technical breakout.
Active icon
Continue Umbrella
Company Update

Palantir Update: What’s behind the volatility?

Following the strong August rally, Palantir is seeing pronounced price swings. Strong growth meets a high valuation and elevated market
Continue Umbrella
Company Update

MUMAK SpotLight of the week: Revolution Medicines with FDA breakthrough. PayPal and Palantir in focus

Revolution Medicines reaches a decisive milestone with the FDA approval of Daraxonrasib. PayPal loses a key short-term price driver as
Continue Umbrella
Company Update

MUMAK SpotLight of the week: Eli Lilly and Palantir in focus

Eli Lilly strengthens its pipeline, Palantir remains volatile, and Johnson & Johnson gains momentum. The most important developments of the
Continue Umbrella
Company Update

MUMAK SpotLight of the week: Five stocks in focus

Eli Lilly, Rheinmetall, Bayer, Palantir, and Revolution Medicines impress with strong developments—but valuation, risks, and chart technicals remain decisive.
Continue Umbrella